August 2020, Drugs Monitor, Page 3

(11 Aug 2020) Lopinavir/R and Hydroxychoroquine- several adverse events and no effect on clinical course

August 20, 2020

Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study https://doi.org/10.1002/jmv.26407 This was a retrospective intent-to-treat analysis of the hospitalized patients who started LPV/r+HCQ between 21 February and 20 March 2020.… Continue reading "(11 Aug 2020) Lopinavir/R and Hydroxychoroquine- several adverse events and no effect on clinical course"

(11 Aug 2020) Hydroxychloroquine- administration in critically ill patients not useful

August 20, 2020

Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results https://doi.org/10.1016/j.ijantimicag.2020.106136 A single-center retrospective study was performed from March to April 2020 in an ICU of a university hospital. All patients admitted to our ICU with a confirmed… Continue reading "(11 Aug 2020) Hydroxychloroquine- administration in critically ill patients not useful"

(11 Aug 2020) Hydroxychloroquine, Lopinavir/R- No statistically significant differences with HCQ or LPV/RTV

August 20, 2020

Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort https://doi.org/10.1007/s00508-020-01720-y Of 156 patients (41% female) with a median age of 72 years (IQR 55.25-81) admitted to our department, 67 patients fulfilled the inclusion criteria (20… Continue reading "(11 Aug 2020) Hydroxychloroquine, Lopinavir/R- No statistically significant differences with HCQ or LPV/RTV"

(10 Aug 2020) Favipiravir-viral clearance in 62.5% of patients within 4 days

August 19, 2020

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://doi.org/10.1093/cid/ciaa1176 In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment… Continue reading "(10 Aug 2020) Favipiravir-viral clearance in 62.5% of patients within 4 days"

(10 Aug 2020) Tocilizumab, Anakinra- Prompt identification and treatment of COVID19-CS prior to intubation important

August 19, 2020

Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab https://www.ijidonline.com/article/S1201-9712(20)30609-3/fulltext In a retrospective cohort study, at tocilizumab initiation (n = 52), 50 (96.2%) were intubated, and only 7 (13.5%) received concomitant corticosteroids. At anakinra initiation (n =… Continue reading "(10 Aug 2020) Tocilizumab, Anakinra- Prompt identification and treatment of COVID19-CS prior to intubation important"

(10 Aug 2020) Tocilizumab-TCZ-treated patients show no disease progression

August 19, 2020

Low-Dose Subcutaneous Tocilizumab to Prevent Disease Progression in Patients with Moderate COVID-19 Pneumonia and Hyperinflammation https://doi.org/10.1016/j.ijid.2020.07.078 Ten consecutive patients (6 males, median age 55 years) treated with TCZ on top of SOC, and ten patients (6 males, median age… Continue reading "(10 Aug 2020) Tocilizumab-TCZ-treated patients show no disease progression"

(06 Aug 2020) Hydroxychloroquine- did not prevent illness compatible with Covid-19

August 8, 2020

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2016638 In this randomized, double-blind, placebo-controlled trial (NCT04308668. opens in new tab), the efficacy of hydroxychloroquine as Covid-19 postexposure prophylaxis was investigated. In this trial, high doses of hydroxychloroquine did… Continue reading "(06 Aug 2020) Hydroxychloroquine- did not prevent illness compatible with Covid-19"

(05 Aug 2020) Favipiravir- demonstrated rapid antiviral response against SARS-CoV-2

August 6, 2020

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial https://doi.org/10.1101/2020.07.26.20154724 In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment… Continue reading "(05 Aug 2020) Favipiravir- demonstrated rapid antiviral response against SARS-CoV-2"

(04 August 2020) Interferons- Higher rate of recovery

August 6, 2020

Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery https://doi.org/10.1101/2020.07.28.20157974.this A prospective observational study (RPCEC00000318) was implemented to monitor a therapeutic intervention with IFN alpha-2b used in the national protocol for COVID-19 attending in Cuba. Patients received therapy… Continue reading "(04 August 2020) Interferons- Higher rate of recovery"

(03 Aug 2020) Lopinavir/R & Chloroquine- did not improve the prognosis or shorten the clinical course of COVID-19

August 4, 2020

A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients https://doi.org/10.1097/QAI.0000000000002452 A retrospective study to summarize the clinical practices of non-severe patients with COVID-19 receiving the standard care, LPV/r or chloroquine was conducted. Of the… Continue reading "(03 Aug 2020) Lopinavir/R & Chloroquine- did not improve the prognosis or shorten the clinical course of COVID-19"

Month: August 2020